Year All2024202320222021202020192018201720162015201420132012201120102007 07.30.14 Entinostat Improves Treatment Outcomes When Combined with Immune Checkpoint Blockade in Preclinical Tumor Models Read More 06.30.14 First Patient Enrolled in ECOG-ACRIN Phase III Trial of Syndax's Entinostat Read More 05.27.14 Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology(ASCO) Annual Meeting pdf Read More 03.28.14 Syndax Files Registration Statement for Proposed Initial Public Offering Read More 03.20.14 ECOG-ACRIN Opens Phase III Trial of Syndax?s Entinostat in Advanced Breast Cancer Read More 02.13.14 Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer Read More 02.03.14 Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director Read More 01.23.14 Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee Read More 11.01.13 Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer Read More 09.11.13 Syndax’s Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer Read More 09.04.13 Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries Read More 08.27.13 Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers Read More
07.30.14 Entinostat Improves Treatment Outcomes When Combined with Immune Checkpoint Blockade in Preclinical Tumor Models Read More
05.27.14 Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology(ASCO) Annual Meeting pdf Read More
02.13.14 Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer Read More
02.03.14 Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director Read More
01.23.14 Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee Read More
11.01.13 Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer Read More
09.11.13 Syndax’s Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer Read More
09.04.13 Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries Read More
08.27.13 Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers Read More